Loading stock data…
$6.96-0.08 (-1.14%)
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia.
Satellos Bioscience Inc. in the Healthcare sector is trading at $6.96 with a market capitalization of $198M. Wall Street consensus targets $24.17 (6 analysts), implying a +247.2% move over the next 12 months. The stock is currently 48% below its 52-week high of $13.39, remaining 18.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.16M↓ | -$10.04M↓ | -$7.65M↓ | -$5.97M↑ | -$6.37M |
| Net Income | -$11.72M↓ | -$9.77M↓ | -$7.30M↓ | -$5.82M↓ | -$5.61M |
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery p...